Christopher D. Pfeiffer

Learn More
BACKGROUND Invasive candidiasis (IC) is a devastating disease. While prompt antifungal therapy improves outcomes, empiric treatment based on the presence of fever has little clinical impact. Β-D-Glucan (BDG) is a fungal cell wall component detectable in the serum of patients with early invasive fungal infection (IFI). We evaluated the utility of BDG(More)
BACKGROUND There is a paucity of clinical trials informing specific questions faced by infectious diseases (ID) specialists. The ClinicalTrials.gov registry offers an opportunity to evaluate the ID clinical trials portfolio. METHODS We examined 40,970 interventional trials registered with ClinicalTrials.gov from 2007-2010, focusing on study conditions and(More)
  • 1